Approval of the Financial Statements for the quarter and financial year ended March 31, 2025 along with the Audit Report and declaration of dividend
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Novartis India, at its May 9, 2025 meeting, approved the audited financial results for Q4 and FY ended March 31, 2025. Revenue from operations grew to ₹3,562.7 million from ₹3,350.7 million, while profit after tax rose to ₹1,009.0 million from ₹851.9 million (up about 18%), translating to EPS of ₹40.87 vs ₹34.50. Statutory auditors BSR & Co. LLP issued an unmodified (clean) opinion on the results. The Board recommended a final dividend of ₹25 per share (same as last year) subject to shareholder approval. It also approved the re-appointment of Mr. Sanker Parameswaran as Independent Director for a second 5-year term and appointed M K Saraf & Associates LLP as Secretarial Auditors for 5 years.
A clean audit opinion, steady dividend of ₹25/share, and ~18% PAT growth signal stable operational performance and continued shareholder returns. The postal ballot item seeking approval for a related-party transaction with parent Novartis Pharma AG is a routine governance matter requiring shareholder nod.